SMART Exercise for PAD (SMART PAD)

April 11, 2026 updated by: Mary McDermott, Northwestern University

Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for Peripheral Artery Disease: The SMART PAD Trial

Supervised exercise therapy (SET), consisting of treadmill exercise conducted three times weekly at a center while supervised by healthcare personnel, is first line therapy for people disabled by lower extremity peripheral artery disease (PAD). However, travelling three times/week to a center for SET is burdensome. Compared to SET, home-based exercise is more accessible and less burdensome. Yet, evidence-based guidelines recommend SET over home-based exercise for PAD. Walking exercise is first line therapy to improve walking distance for PAD, but it does not eliminate ischemic leg symptoms in most people with PAD. The investigators' work and that of others showed that nitrate-rich beetroot juice, which increases plasma nitrite, limb perfusion, and skeletal muscle function, significantly improved exercise tolerance and reduced non-response to exercise in people with and without PAD. The investigators will use a 2 x 2 factorial design to address two major barriers to achieving benefits from exercise therapy for PAD: First, guideline recommendations for supervised exercise therapy (SET) as first line therapy for PAD. Second, the inability of exercise therapy to eliminate PAD-related disability in most people with PAD. Participants will be randomized to one of four groups for 12 weeks: Supervised treadmill exercise + nitrate rich beetroot juice; supervised treadmill exercise + placebo, home-based walking exercise + nitrate rich beetroot juice, home-based walking exercise + placebo.

Study Overview

Detailed Description

Supervised exercise therapy (SET), consisting of treadmill exercise conducted three times weekly at a center while supervised by healthcare personnel, is first line therapy for people disabled by lower extremity peripheral artery disease (PAD). However, travelling three times/week to a center for SET is burdensome. As of 2018, only 1.3% of patients with Medicare and symptomatic PAD had enrolled in SET. Compared to SET, home-based exercise is more accessible and less burdensome. Yet, evidence-based guidelines recommend SET over home-based exercise for PAD. In 2021, the investigators reported that a home-based exercise intervention that incorporated behavioral methods significantly improved six-minute walk in PAD, compared to an attention control group. But no randomized trials have compared SET to a home-based exercise intervention that incorporated behavioral change methods in PAD. However, 45% of people with PAD do not meaningfully respond to exercise interventions, defined as failure to improve six-minute walk by > 20 meters. This phenomenon occurs for both supervised and home-based exercise. The investigators' work and that of others showed that nitrate-rich beetroot juice, which increases plasma nitrite, limb perfusion, and skeletal muscle function, significantly improved exercise tolerance and reduced non-response to exercise in people with and without PAD. Therefore, the investigators will use a 2 x 2 factorial design to address two major barriers to achieving benefits from exercise therapy for PAD: First, guideline recommendations for supervised exercise therapy (SET) as first line therapy for PAD. Second, the inability of exercise therapy to eliminate PAD-related disability in most people with PAD. In this 2 x 2 factorial design, participants will be randomized to one of four groups for 12 weeks: Supervised treadmill exercise + nitrate rich beetroot juice; supervised treadmill exercise + placebo, home-based walking exercise + nitrate rich beetroot juice, home-based walking exercise + placebo.

Study Type

Interventional

Enrollment (Estimated)

210

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Illinois
      • Chicago, Illinois, United States, 60637
      • Chicago, Illinois, United States, 60611
        • Recruiting
        • Northwestern University Feinberg School of Medicine
        • Principal Investigator:
          • Mary M McDermott, MD
        • Contact:
    • Minnesota
      • Minneapolis, Minnesota, United States, 55455
        • Recruiting
        • University of Minnesota
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

First, all participants will be age 50 and older. Second, all participants will have PAD. PAD will be defined as either:

  1. An ABI <= 0.90 at baseline.
  2. Vascular lab evidence of PAD (such as a toe brachial pressure less than or equal to 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities.
  3. An ABI of >0.90 and <1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test.

Exclusion Criteria:

  1. Above- or below-knee amputation
  2. Limb-threatening ischemia defined as an ABI <0.40 with symptoms of rest pain
  3. Wheelchair confinement or requiring a walker to ambulate
  4. Walking is limited by a condition other than PAD
  5. Current foot ulcer on bottom of foot
  6. Unwilling to drink beetroot juice
  7. Unwilling to accept randomization into either group (home based exercise or supervised exercise)
  8. Planning to engage in new walking exercise outside of the study or unwilling to refrain from new walking exercise activity during the trial.
  9. Already exercising at a level consistent with exercise intervention.
  10. End-stage kidney disease (ESKD) associated with the need for dialysis.
  11. Planned major surgery, coronary or leg revascularization during the next six months
  12. Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months
  13. Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. [NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent. Participants who require oxygen only at night may still qualify.]
  14. Mini-Mental Status Examination (MMSE) score < 23 or dementia. However, if the MMSE is < 23 and the Principal Investigator evaluation determines that the lower score is related to language barriers or education level, the Principal Investigator has discretion to allow a participant with MMSE < 23 to participate, as appropriate.
  15. Allergy to beetroot juice
  16. Currently consuming beetroot juice or oral nitrate or nitrite, or a beetroot supplement, and/or unwilling to avoid these during study participation. Participants currently consuming one cup of beets daily will be asked to discontinue beet ingestion for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from daily beet consumption of one cup or more, they will not be eligible for the clinical trial.
  17. Unstable angina
  18. Abnormal baseline stress test without subsequent clearance for exercise by physician
  19. Non-English speaking. The SMART PAD interventions are delivered by interventionists who do not speak non-English languages. The integrity of the clinical trial requires clear and effective communication for data collection and intervention delivery. The trial does not have staff members who are fluent in non-English languages, nor does it have the ability to translate all study materials into other languages.
  20. Participation in or completion of a clinical trial in the previous three months. [NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.] Participants in a study that involved up to three single doses of nitrate-rich beetroot juice administered on separate days may participate if a month has passed since their last dose of nitrate-rich beetroot juice.
  21. Visual impairment that limits walking ability.
  22. Baseline blood pressure <100/45.
  23. Participation in a supervised treadmill exercise program or cardiac rehabilitation program in previous three months.
  24. Using a mouthwash containing chlorhexidine or cetylpyridinium chloride or a mouthwash determined to be bactericidal and unwilling to discontinue.
  25. An eGFR value <30 or potassium >5.0.
  26. History of kidney stones that requires minimized intake of oxalate. Potential participants who need to minimize oxalate intake will be excluded from the trial.
  27. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Supervised treadmill exercise + nitrate rich beetroot juice
This group will be participating in Supervised Treadmill Exercise and drinking nitrate rich beetroot juice for 12 weeks.
This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.
Participants will drink one shot of nitrate rich beet-root juice twice daily for 12 weeks.
Placebo Comparator: Supervised treadmill exercise + placebo
This group will be participating in Supervised Treadmill Exercise and drinking placebo beetroot juice with nitrate removed for 12 weeks.
This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.
Experimental: Home-based walking exercise + nitrate rich beetroot juice
This group will be participating in Home-Based Exercise and drinking nitrate rich beetroot juice for 12 weeks.
Participants will drink one shot of nitrate rich beet-root juice twice daily for 12 weeks.
This is a 12 week intervention where participants will walk at home for exercise with guidance from a study coach. They will have 4 in person visits in the first four weeks and then have weekly phone calls in the last 8 weeks of the intervention with their coach.
Placebo Comparator: Home-based walking exercise + placebo
This group will be participating in Home-Based Exercise and drinking placebo beetroot juice with nitrated removed for 12 weeks.
This is a 12 week intervention where participants will walk at home for exercise with guidance from a study coach. They will have 4 in person visits in the first four weeks and then have weekly phone calls in the last 8 weeks of the intervention with their coach.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Six-Minute Walk Distance
Time Frame: Measured at baseline and 12 week follow-up
Change in six-minute walk distance
Measured at baseline and 12 week follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Walking Impairment Questionnaire (WIQ) Distance Score
Time Frame: measured at baseline and 12 weeks
WIQ distance score - Range 0-100, 100 is best.
measured at baseline and 12 weeks
20-meter Improvement in Six-Minute Walk Distance
Time Frame: measured at 12 weeks
Meaningful response to exercise interventions
measured at 12 weeks
Step Count
Time Frame: measured at baseline and 12 weeks
Step count measured over seven days with the FITBIT
measured at baseline and 12 weeks
Six-Minute Walk Distance
Time Frame: Measured at baseline and 24-week follow up
Change in six-minute walk distance
Measured at baseline and 24-week follow up
PROMIS Mobility Questionnaire Score
Time Frame: measured at baseline and 12 weeks
PROMIS mobility score from administered PROMIS questionnaire. Score range is from zero to infinity and a higher score means a better outcome.
measured at baseline and 12 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physical Activity Step Count
Time Frame: Measured at baseline and 24 weeks
Step count measured over seven days with FITBIT
Measured at baseline and 24 weeks
Physical activity distance
Time Frame: Measured at baseline and 24 weeks.
Physical activity distance measured over seven days with FITBIT
Measured at baseline and 24 weeks.
Short physical performance battery (SPPB)
Time Frame: measured at baseline and 12 weeks
SPPB range, range 0-12, 12-best
measured at baseline and 12 weeks
Walking Impairment Questionnaire (WIQ) Stair Climbing Score
Time Frame: measured at baseline and 12 weeks
WIQ stair climbing score from administered WIQ, range 0-100, 100 is best.
measured at baseline and 12 weeks
Walking Impairment Questionnaire (WIQ) Walking Speed Score
Time Frame: measured at baseline and 12 weeks
WIQ walking speed score from administered WIQ, range 0-100, 100 is best
measured at baseline and 12 weeks
Walking Impairment Questionnaire (WIQ) Stair Climbing Score
Time Frame: measured at baseline and 24 weeks
WIQ stair climbing score from administered WIQ, range 0-100, 100 is best
measured at baseline and 24 weeks
Walking Impairment Questionnaire (WIQ) Walking Speed Score
Time Frame: measured at baseline and 24 weeks
WIQ walking speed score from administered WIQ, range 0-100, 100 is best
measured at baseline and 24 weeks
Short physical performance battery (SPPB)
Time Frame: measured at baseline and 24 weeks
SPPB range, range 0-12, 12-best
measured at baseline and 24 weeks
Physical Activity Total Distance
Time Frame: Measured at baseline and 12 weeks
Distance walked over seven days measured with FITBIT
Measured at baseline and 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 8, 2023

Primary Completion (Estimated)

November 1, 2028

Study Completion (Estimated)

March 31, 2029

Study Registration Dates

First Submitted

May 22, 2023

First Submitted That Met QC Criteria

September 7, 2023

First Posted (Actual)

September 11, 2023

Study Record Updates

Last Update Posted (Actual)

April 15, 2026

Last Update Submitted That Met QC Criteria

April 11, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Peripheral Arterial Disease

Clinical Trials on Supervised Treadmill Exercise

Subscribe